0QAI.L - Adocia SA

LSE - LSE Delayed price. Currency in EUR
3.8750
+0.1000 (+2.65%)
At close: 05:43PM BST
Stock chart is not supported by your current browser
Previous close3.7750
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Volume26,313
Avg. volume781
Market cap270,410
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)-3.2240
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Listing of ADOCIA Shares Suspended

    LYON, France, June 01, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it has asked Euronext to suspend the listing of its shares on the Euronext Paris regulated market as of today, pending a press release.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of April 30th, 2023

    LYON, France, May 16, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovativ

  • Business Wire

    ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer

    LYON, France, May 15, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the appointment of Olivier Soula as Chief Executive Officer of Adocia, by decision of the Board of Directors which met on May 11, 2023, in Paris. Olivier Soula succeeds Gérard Soula, whose term as Chairman of the B

  • Business Wire

    ADOCIA Announces the Release of its Universal Registration Document for the Year 2022

    LYON, France, April 27, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the filing of its 2022 Universal Registration Document with the "Autorité des marchés financiers" (AMF - the French financial markets regulator) on April 26, 2023.

  • Business Wire

    ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities

    LYON, France, April 25, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports today its first quarter financial results for 2023 and provides an update on its activities.

  • Business Wire

    ADOCIA Announces Its Annual Shareholders’ Meeting to Be Held on May 11, 2023 in Paris

    LYON, France, April 20, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting ("AGM") on May 11, 2023, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin, 75001 Paris.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of March 31st, 2023

    LYON, France, April 13, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovat

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of February 28th, 2023

    LYON, France, March 17, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovat

  • Business Wire

    ADOCIA Announces Its Annual Results for 2022 and Provides Corporate and Financial Update

    LYON, France, March 15, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its annual financial results as of December 31, 2022. The consolidated financial statements were approved by the board of directors on March 14, 2023 and the audit of the accounts is being finalized.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of January 31st, 2023

    LYON, France, February 15, 2023--Regulatory News: ADOCIA (Paris:ADOC):

  • Business Wire

    Adocia Publishes Its Letter to Shareholders

    LYON, France, January 30, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the January 2023 Letter to Shareholders.

  • Business Wire

    ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets

    LYON, France, January 23, 2023--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31st, 2022:

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of December 31st, 2022

    LYON, France, January 16, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, releases its total number of outstanding shares as well as its voting rights as of December 31st, 2022.

  • Business Wire

    ADOCIA Announces its Financial Calendar for 2023

    LYON, France, January 12, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today its financial calendar for 2023.

  • Business Wire

    ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao

    LYON, France, December 29, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today new positive results for BioChaperone® Lispro insulin (named THDB0206 in China) with partner Tonghua Dongbao.

  • Business Wire

    ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023

    LYON, France, December 21, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its participation to the following investors events:

  • Business Wire

    Number of shares and voting rights of ADOCIA as of November 30th, 2022

    LYON, France, December 15, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno

  • Business Wire

    Adocia Strengthens Its Cash Position with EUR 6 Million Through the Issuance of Convertible Bonds Subscribed by European Investors in Order to Accelerate the Development of Key Products

    LYON, France, December 01, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today the completion of a EUR 6 million financing operation.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of October 31st, 2022

    LYON, France, November 16, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno

  • Business Wire

    ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates

    LYON, France, October 25, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of September 30th, 2022

    LYON, France, October 13, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innov

  • Business Wire

    ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis

    LYON, France, October 06, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005658/en/

  • Business Wire

    ADOCIA: Upcoming Investor Meetings

    LYON, France, October 03, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will attend the following investor events:

  • Business Wire

    ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update

    LYON, France, September 19, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its financial results for the six months ended June 30th, 2022.

  • Business Wire

    Adocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th

    LYON, France, September 15, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, will release its first-half 2022 results on September 19th, 2022, post-market close.